Skip to content
Open access

ESCAPE: assigning site-specific activity to covalent ligands in cells by prime editing

Jul 2026 · bioRxiv · 0 citations · 69 references
Medicine Biology

TL;DR

ESAPE (Endogenous Site-specific Competition Assays using Prime Editors using Prime Editors), a platform for the site-resolved functional analysis of covalent ligands in cells, identifies multiple covalent ligand-protein interactions that impair cancer cell growth.

Abstract

Chemical proteomics has identified covalent ligands targeting cysteine residues across many hundreds of human proteins. The functional effects of these liganding events, however, remain challenging to assign at scale. Here we describe ESCAPE (Endogenous Site-specific Competition Assays using Prime Editors), a platform for the site-resolved functional analysis of covalent ligands in cells. In this method, cysteine-to-serine substitutions are generated by prime editing to abrogate covalent ligand-protein interactions, and the impact of these edits on ligand-induced cellular phenotypes is quantified through allele frequency-based resistance scores. Applied to ligandable cysteines mapped by activity-based protein profiling in 50+ proteins, ESCAPE identified multiple covalent ligand-protein interactions that impair cancer cell growth, including azetidine butynamides that target a non-orthosteric cysteine in the RNA helicase DDX49 to disrupt 18S rRNA processing, 40S ribosome assembly, and protein synthesis. ESCAPE thus provides a scalable framework for the functional characterization of covalent ligands targeting structurally and mechanistically diverse proteins.

Read PDF

Similar papers

Open access Aug 2026

Profiling Protein‐Peptide Interactions by Yeast Surface Display

A protocol for discovering protein‐binding peptides using a very large, target‐agnostic yeast surface display library containing approximately 6.1 × 109 unique clones and providing broad coverage of short peptide sequence space is described.

J. D. Hurley, Andrew C. Kruse · 0 citations
Aug 2026

Post-translational chemical modification of E3 ligase for efficient target protein degradation.

This work reports the first ligand-directed chemical strategy that converts transient PROTAC-mediated ternary complex formation into binary target recognition via post-translational chemical modification of an E3 ligase, and believes it could provide a platform for next-generation targeted protein degraders to overcome...

Eunbin Park, Jinjoo Jung, G. J. Kumar et al. · 0 citations
Aug 2026

Accurate Identification of Covalently Ligandable Cysteines Using CCSite.

Targeted covalent inhibition is an important strategy in modern drug discovery, with cysteine being the most common residue targeted for covalent ligands. Accurate identification of covalently ligandable cysteines is therefore essential, especially for traditionally "undruggable" targets. However, structure-based metho...

Yan-Lin Ren, M. Mou, Yi-Miao Zhu et al. · 0 citations
Aug 2026

Mapping the covalent cysteine interactome of Ebselen reveals high-sensitivity target engagement and redox proteome remodeling.

Ebselen is a covalent organoselenium compound with broad pharmacological activity, yet its cellular cysteine targets and downstream proteomic consequences remain incompletely defined. Here, we integrated competitive gel-based activity-based protein profiling, reactivity-dependent tandem orthogonal proteolysis-activity-...

Yi-Ru Liu, Yu-Qiu Zi, Zhongyao Jiang et al. · 0 citations
Open access Sep 2026

Structure-function analysis of PI3K signalling cascade base editing screens in cancer cells

Knowledge of protein structure and function underpins rational drug discovery, yet many targets lack known selectively druggable sites. Furthermore, the identification of secondary druggable sites offers a strategy to overcome drug resistance. Fragment-based drug discovery (FBDD) can identify new ligandable binding poc...

Katrina McCarten, Bárbara Abreu, Benoit Baillif et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.